Trial Profile
A multicenter, double-blind, placebo-controlled study to investigate the effects of oral everolimus alone or in combination with BEZ235 on the immune response to influenza vaccination in the elderly at increased risk of influenza illness
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Jul 2019
Price :
$35
*
At a glance
- Drugs Dactolisib (Primary) ; Everolimus (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics
- Sponsors resTORbio
- 02 Nov 2018 Status changed from not yet recruiting to completed.
- 14 Mar 2018 New trial record